



**MYRIAD GENETICS, INC.
RESEARCH AND PRODUCT INNOVATION COMMITTEE CHARTER**

PURPOSE

The purpose of the Research and Product Innovation Committee ("Committee") of the Board of Directors ("Board") of Myriad Genetics, Inc. ("Company") is to assist the Board in its oversight responsibilities by advising and consulting with the Company's management relating to product research, development and strategy.

In addition, the Committee will undertake the specific duties and responsibilities listed below and other duties as the Board prescribes.

ORGANIZATION

Charter. The charter shall be reviewed at least annually by the Committee and changes proposed by the Committee shall be submitted to the Board for approval.

Members. The Committee shall be composed of three members. Each member shall be a non-employee director of the company. The entire Committee or any individual member of the Committee may be removed without cause by the affirmative vote of the majority of the Board. Any Committee member may resign effective upon giving oral or written notice to the Chair of the Board (unless the notice specifies a later time for the effectiveness of such resignation). The Nominating and Governance Committee may recommend, and the Board may elect, a successor to assume the available position on the Committee when the resignation becomes effective.

The Chair of the Committee will be selected by the Chair of the Board. The Chair of the Committee shall determine the agenda for and the length of meetings and shall have unlimited access to management and information relating to the Committee's purposes. Meeting agendas will be prepared and, to the extent practicable, provided in advance to the members of the Committee, along with appropriate briefing materials. The Chair of the Committee may establish such other rules as may from time to time be necessary and proper for the conduct of the business of the Committee.

Meetings, Minutes, Reporting. The Committee shall meet not less than two (2) times per year at such times and places as the Chair shall determine. All Committee members are expected to attend each meeting, in-person or via tele- or video conference. The Committee shall keep minutes of the proceedings of the Committee and the Committee shall report its activities to the full Board. The Chair of the Committee shall make an annual presentation to the Board regarding the Committee's activities and initiatives. The Committee may appoint a Secretary who shall keep records of the Committee proceedings. The Secretary need not be a director and shall have no membership or voting rights by virtue of the position.

Access to Officers and Employees. The Committee shall have the power to meet with any officer or employee of the Company and may invite any such persons to attend a Committee meeting.

Authority to Retain Advisors. The Committee shall have the authority, at the Company's expense and without needing to seek approval from the Board, to retain and terminate consultants, legal counsel, or other advisors, as the Committee deems advisable, including the sole authority to approve any such advisors' fees and retention terms.

Compensation. Committee members shall be compensated by the Company in the form of directors' fees, which may be paid in cash or equity of the Company. No compensation shall be paid to any Committee member who also serves as an officer of the Company.

RESPONSIBILITIES

The Board delegates certain responsibilities to the Committee to assist the Board in fulfilling its oversight duties.

The Committee shall interact with the Company's Chief Science Officer and other management and external advisors to create insights and recommendations regarding the following aspects of the Company's pipeline development and technical and commercial innovation:

- Maintaining alignment between strategic commercial objectives and the Company's product development;
- Identification, evaluation and oversight of appropriate pipeline, technology, and product development investments;
- Prioritizing the innovation and technology needs of the company;
- Establishing practices and procedures to ensure that the Company's existing and new product technologies are developed and commercialized in compliance with applicable safety, health and regulatory principles and requirements;
- Recruitment and interactions with the Company's scientific advisory board;
- Early stage evaluation for merger and acquisition opportunities that would expand the Company's pipeline or product offerings.

The Committee shall (1) advise management on all clinical trials and interactions with regulatory authorities, including the Food and Drug Administration; (2) evaluate existing and additional training for research and development personnel associated with the conduct of clinical test studies and the disclosure thereof; and (3) advise the Board on clinical trials and any problems arising therefrom.

The Committee shall regularly consult with Company management and the Board concerning identified risks related to the development, acquisition, management, protection of intellectual property, and commercialization of the Company's product technologies.

Version: November 2024